Welcome to Hobson Prior

Hobson Prior is an award-winning staffing services business focused on the global life sciences industry.

We specialise in the source and supply of mid to upper level clinical, medical and regulatory specialists involved in drug discovery, clinical development and post-approval processes.

Please click here to view our client brochure

 

Clients

Click here for more information about us, our services and our global compliance commitment.

Candidates

Click here for information on contracting in the UK, Switzerland and Internationally, and access to our contractor portal.

Candidates Login

Vacancy Search

Quick job search

Advanced Search

Latest News

All eyes on brodalumab fallout

After Amgen’s shock decision on Friday to dump the AstraZeneca-partnered psoriasis antibody brodalumab, citing risk of suicide, attention should turn to competing agents from Novartis and...

Bayer's Stivarga wins appeal to stay on CDF

Bayer's Stivarga wins appeal to stay on CDF

BMA slams seven-day GP services 'obsession'

BMA slams seven-day GP services 'obsession'

Upcoming events: a dosing decision for BioMarin, plus Roche to get Alzheimer’s data

Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from BioMarin’s phase II trial of the achondroplasia project BMN 111, expected this month or next, will...

Surprise resurrection sees Aveo and Prima pining for the fjords

When it comes to dead parrots making comebacks it could not have got much more extreme than the severely depressed Aveo Oncology and Prima Biomed, whose apparently deceased oncology projects...

Novartis' Afinitor extends progression-free survival in NET

Novartis' Afinitor extends progression-free survival in NET

Regeneron/Sanofi drug improves RA symptoms in PhIII trial

Regeneron/Sanofi drug improves RA symptoms in PhIII trial

Boehringer, Eureka in intra-cellular antibodies pact

Boehringer, Eureka in intra-cellular antibodies pact

Could you be the PharmaTimes Marketer of the Year 2015?

Could you be the PharmaTimes Marketer of the Year 2015?

Novartis COPD therapies hit Phase III targets

Novartis COPD therapies hit Phase III targets
more news